CN114026071B - N-(4-(4-(环丙基甲基)哌嗪-1-羰基)苯基)喹啉-8-磺酰胺的结晶盐形式 - Google Patents

N-(4-(4-(环丙基甲基)哌嗪-1-羰基)苯基)喹啉-8-磺酰胺的结晶盐形式 Download PDF

Info

Publication number
CN114026071B
CN114026071B CN202080045139.1A CN202080045139A CN114026071B CN 114026071 B CN114026071 B CN 114026071B CN 202080045139 A CN202080045139 A CN 202080045139A CN 114026071 B CN114026071 B CN 114026071B
Authority
CN
China
Prior art keywords
crystalline form
crystalline
compound
certain embodiments
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080045139.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN114026071A (zh
Inventor
L.M.格罗夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agios Pharmaceuticals Inc
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Priority to CN202410205860.2A priority Critical patent/CN118206485A/zh
Publication of CN114026071A publication Critical patent/CN114026071A/zh
Application granted granted Critical
Publication of CN114026071B publication Critical patent/CN114026071B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202080045139.1A 2019-05-22 2020-05-21 N-(4-(4-(环丙基甲基)哌嗪-1-羰基)苯基)喹啉-8-磺酰胺的结晶盐形式 Active CN114026071B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410205860.2A CN118206485A (zh) 2019-05-22 2020-05-21 N-(4-(4-(环丙基甲基)哌嗪-1-羰基)苯基)喹啉-8-磺酰胺的结晶盐形式

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962851344P 2019-05-22 2019-05-22
US62/851,344 2019-05-22
PCT/US2020/033992 WO2020237047A1 (en) 2019-05-22 2020-05-21 Crystalline salt forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410205860.2A Division CN118206485A (zh) 2019-05-22 2020-05-21 N-(4-(4-(环丙基甲基)哌嗪-1-羰基)苯基)喹啉-8-磺酰胺的结晶盐形式

Publications (2)

Publication Number Publication Date
CN114026071A CN114026071A (zh) 2022-02-08
CN114026071B true CN114026071B (zh) 2024-03-01

Family

ID=71016713

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080045139.1A Active CN114026071B (zh) 2019-05-22 2020-05-21 N-(4-(4-(环丙基甲基)哌嗪-1-羰基)苯基)喹啉-8-磺酰胺的结晶盐形式
CN202410205860.2A Pending CN118206485A (zh) 2019-05-22 2020-05-21 N-(4-(4-(环丙基甲基)哌嗪-1-羰基)苯基)喹啉-8-磺酰胺的结晶盐形式

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410205860.2A Pending CN118206485A (zh) 2019-05-22 2020-05-21 N-(4-(4-(环丙基甲基)哌嗪-1-羰基)苯基)喹啉-8-磺酰胺的结晶盐形式

Country Status (9)

Country Link
US (1) US20230192618A1 (https=)
EP (1) EP3972957A1 (https=)
JP (1) JP2022533227A (https=)
CN (2) CN114026071B (https=)
AU (1) AU2020280045A1 (https=)
CA (1) CA3145138A1 (https=)
IL (1) IL288158A (https=)
MX (2) MX2021014228A (https=)
WO (1) WO2020237047A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312679A (en) 2021-11-16 2024-07-01 Agios Pharmaceuticals Inc Compounds for the treatment of anemia associated with MDS and other conditions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102481300A (zh) * 2009-06-29 2012-05-30 安吉奥斯医药品有限公司 治疗性化合物和组合物
WO2016201227A1 (en) * 2015-06-11 2016-12-15 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7998505B2 (en) * 2006-10-27 2011-08-16 Fmc Corporation Dry granulation binders, products, and use thereof
TWI730959B (zh) * 2015-05-19 2021-06-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺
KR102777452B1 (ko) * 2017-11-22 2025-03-10 아지오스 파마슈티컬스 아이엔씨. N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의결정 형태

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102481300A (zh) * 2009-06-29 2012-05-30 安吉奥斯医药品有限公司 治疗性化合物和组合物
WO2016201227A1 (en) * 2015-06-11 2016-12-15 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency;Charles Kung et al.;blood;第130卷(第11期);1347-1356 *

Also Published As

Publication number Publication date
AU2020280045A1 (en) 2021-12-23
IL288158A (en) 2022-01-01
MX2024009648A (es) 2024-08-19
CN118206485A (zh) 2024-06-18
US20230192618A1 (en) 2023-06-22
CN114026071A (zh) 2022-02-08
WO2020237047A1 (en) 2020-11-26
EP3972957A1 (en) 2022-03-30
JP2022533227A (ja) 2022-07-21
CA3145138A1 (en) 2020-11-26
MX2021014228A (es) 2022-02-21

Similar Documents

Publication Publication Date Title
TWI808108B (zh) N-(4-(4-(環丙基甲基)哌嗪-1-羰基)苯基)喹啉-8-磺醯胺之結晶型
EP4010322B1 (en) Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof
CN114026071B (zh) N-(4-(4-(环丙基甲基)哌嗪-1-羰基)苯基)喹啉-8-磺酰胺的结晶盐形式
KR20250125432A (ko) 이브루티닙을 포함하는 제형/조성물
TWI922809B (zh) N-(4-(4-(環丙基甲基)哌嗪-1-羰基)苯基)喹啉-8-磺醯胺之結晶型
HK40104405A (en) Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
EA042666B1 (ru) Кристаллические формы n-(4-(4-(циклопропилметил)пиперазин-1-карбонил)фенил)хинолин-8-сульфонамида

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant